{"id":732360,"date":"2023-02-16T16:28:08","date_gmt":"2023-02-16T21:28:08","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/"},"modified":"2023-02-16T16:28:08","modified_gmt":"2023-02-16T21:28:08","slug":"vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/","title":{"rendered":"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SAN CARLOS, Calif., Feb.  16, 2023  (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and provide a business update.<\/p>\n<p>Those who would like to participate may access the live webcast\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=LnuD3Cc0RCUiVVxQpQV16bauAMNVK9XgDUkLDxuOZEjnXGCwGnrO113mK9dD1UtFlV9aYd52fpc99m1dN7PVzTr4snZQjW4i6_LmTi-YytE=\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>, or register in advance for the teleconference\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=sxlJ7g0AhPJ1SbmAJeqfEMn2I4xuyNnMS1Kuqt7goNLQ_AdSi4LnCyHnUvMDOzrIq7HZ7SG3BQ-vPtBH8fYTRG3TqS0RqCJ1bo_Q6hoLkpvEBgCp00VlsKAj16hO9F2OAVrww0kxes89ql1sDQmtpQ==\" rel=\"nofollow noopener\" target=\"_blank\">here<\/a>. A live webcast of the conference call will also be available on the investor relations page of the\u00a0Vaxcyte corporate website at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kkWUvg0OB4MqTQAYfxHn3kl_e_ylwiR-urWiU--yRBzBtHTlNr6Ky7PT92aMSfhf-EZYNp8Amxz557jNx96Z1Q==\" rel=\"nofollow noopener\" target=\"_blank\">www.vaxcyte.com<\/a>. After the live webcast, the event will remain archived on the\u00a0Vaxcyte website for 30 days.<\/p>\n<p>\n        <strong>About Vaxcyte <\/strong><br \/>\n        <br \/>Vaxcyte is a vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. The Company is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Vaxcyte\u2019s lead candidate, VAX-24, is a 24-valent, broad-spectrum, carrier-sparing pneumococcal conjugate vaccine, or PCV, being developed for the prevention of invasive pneumococcal disease. Vaxcyte is re-engineering the way highly complex vaccines are made through modern synthetic techniques, including advanced chemistry and the XpressCF\u2122 cell-free protein synthesis platform, exclusively licensed from Sutro Biopharma, Inc. Unlike conventional cell-based approaches, the Company\u2019s system for producing difficult-to-make proteins and antigens is intended to accelerate its ability to efficiently create and deliver high-fidelity vaccines with enhanced immunological benefits. Vaxcyte\u2019s pipeline also includes VAX-31, a 31-valent PCV candidate; VAX-A1, a prophylactic vaccine candidate designed to prevent Group A Strep infections; and VAX-PG, a therapeutic vaccine candidate designed to slow or stop the progression of periodontal disease. Vaxcyte is driven to eradicate or treat invasive bacterial infections, which have serious and costly health consequences when left unchecked. For more information, visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=kkWUvg0OB4MqTQAYfxHn3koCOgXSvoE9r03NVxAzPsUv7sSLolehjbO153SgtirB4EeZoVIcKkczvcADnZM0fg==\" rel=\"nofollow noopener\" target=\"_blank\">www.vaxcyte.com<\/a>.<\/p>\n<p>\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Jennifer Zibuda, Senior Director, Investor Relations<br \/>Vaxcyte, Inc.<br \/>860-729-8902<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=gf721emYxep_S6o5GexfI9r4BPqvEEjxQF2qMUts0wg1p3wPNd3Tc9iEmnDvrUjw69f2_YtKUphqw_UIsEqIkmaW6xrHkQLbh1FAOMQpex0=\" rel=\"nofollow noopener\" target=\"_blank\">investors@vaxcyte.com<\/a><\/p>\n<p>Janet Graesser, Vice President, Corporate Communications and Investor Relations <br \/>Vaxcyte, Inc.<br \/>917-685-8799<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=AxAnICUuKd-W4goidG5FlFPY6UdIscSvZVtyRILcu-w1JD0KFbxppDY_ZyALURpP_KdTKzGe2YSqNICtIvOUTA==\" rel=\"nofollow noopener\" target=\"_blank\">media@vaxcyte.com<\/a><\/p>\n<\/p>\n<p>      <img decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/ZDVhMTc0ZGEtODljNy00NTg5LWIyY2YtYjc0YzkzZWY0MzZiLTEyMDczNzc=\/tiny\/Vaxcyte-Inc-.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and provide a business update. Those who would like to participate may access the live webcast\u00a0here, or register in advance for the teleconference\u00a0here. A live webcast of the conference call will also be available on the investor relations page of the\u00a0Vaxcyte corporate &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-732360","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and provide a business update. Those who would like to participate may access the live webcast\u00a0here, or register in advance for the teleconference\u00a0here. A live webcast of the conference call will also be available on the investor relations page of the\u00a0Vaxcyte corporate &hellip; Continue reading &quot;Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-16T21:28:08+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023\",\"datePublished\":\"2023-02-16T21:28:08+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/\"},\"wordCount\":365,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/\",\"name\":\"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=\",\"datePublished\":\"2023-02-16T21:28:08+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/","og_locale":"en_US","og_type":"article","og_title":"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 - Market Newsdesk","og_description":"SAN CARLOS, Calif., Feb. 16, 2023 (GLOBE NEWSWIRE) &#8212; Vaxcyte, Inc. (Nasdaq: PCVX), a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases, today announced that it will report financial results for the fourth quarter and full year 2022 after market close on February 27, 2023. Company management will host a conference call and webcast beginning at 4:30 p.m. ET \/ 1:30 p.m. PT that day to discuss the financial results and provide a business update. Those who would like to participate may access the live webcast\u00a0here, or register in advance for the teleconference\u00a0here. A live webcast of the conference call will also be available on the investor relations page of the\u00a0Vaxcyte corporate &hellip; Continue reading \"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-02-16T21:28:08+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023","datePublished":"2023-02-16T21:28:08+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/"},"wordCount":365,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/","name":"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=","datePublished":"2023-02-16T21:28:08+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODc0ODM3MiM1NDAzODg3IzIxOTU4MjQ="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/vaxcyte-to-report-fourth-quarter-and-full-year-2022-financial-results-on-february-27-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Vaxcyte to Report Fourth Quarter and Full Year 2022 Financial Results on February 27, 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732360","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=732360"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/732360\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=732360"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=732360"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=732360"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}